NRAS and cancer: Unfortunately, KRAS and NRAS, the major RAS isoforms that are mutated in adult cancers, can be alternatively prenylated by gerangeranyltransferases [116,117,118], and FTIs failed in Phase III clinical trials for KRAS-mutated colorectal [119] and pancreatic [120] cancers.